ULTRAHITMAB
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

ULTRAHITMAB Trademark

Serial Number: 79441828

ULTRAHITMAB is a trademark filed by Zhuhai Trinomab Pharmaceutical Co., Ltd. on November 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Zhuhai Trinomab Pharmaceutical Co., Ltd. (9 trademarks)

Rm.110, 1/F., Plant Building 6,

Entity Type: 99

Trademark Details

Filing Date

November 12, 2025

Registration Date

Not Registered

Goods & Services

Retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; Marketing services; Commercial administration of the licensing of the goods and services of others; Presentation of goods on communication media, for retail purposes in the nature of computerized online ordering services in the field of pharmaceutical, veterinary and sanitary preparations and medical supplies; Presentation of goods on communication media, for retail purposes, namely, providing television home shopping services in the field of general consumer merchandise; Advertising services

Vaccines; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment of kidney disease; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer; Drugs for medical purposes, namely, pharmaceutical preparations for the prevention and treatment of respiratory system disorders; Drugs for medical purposes, namely, pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; Drugs for medical purposes, namely, pharmaceutical preparations for the prevention and treatment of infectious diseases, pain, cancer and tumors; Drugs for medical purposes, namely, pharmaceutical preparations for the prevention and treatment of blood disorders, metabolic and neurological disorders; Biological preparations for medical purposes, namely, biological reagents for medical purposes; Biological preparations for medical purposes, namely, biological preparations for the treatment of cancer; Biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; Biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; Biological preparations for medical purposes for the prevention and treatment of infectious diseases, pain, cancer and tumors; Biological preparations for medical purposes for the prevention and treatment of blood disorders, metabolic and neurological disorders; Antiallergic medicines for human purposes; Medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer and antibiotics; Medicines for human purposes for the prevention and treatment of respiratory system disorders; Medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; Medicines for human purposes for the prevention and treatment of infectious diseases, pain, cancer and tumors; Medicines for human purposes for the prevention and treatment of blood disorders, metabolic and neurological disorders; Diagnostic preparations for medical purposes; Dietetic preparations adapted for medical use; Dietetic foods and beverages adapted for medical use; Protein supplements for animals; Absorbent cotton for medical purposes

Technological research in the field of pharmaceuticals; Technological research in the fields of genetics, genetic engineering, molecular biology and cellular immunology; Technological research in the field of medicine; Research in the field of genetic modification technology; chemical analysis; Chemistry services in the nature of chemist services; Chemistry services, namely, consultation, research and advice; Medical research; laboratory services for biomanufacturing; Scientific research in the nature of clinical trials for others; Computer programming; Providing online non-downloadable computer software for scientific analysis of pharmacological effects of medicines; Rental of scientific microscopes

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 16, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 16, 2026 TROA
REFUSAL PROCESSED BY IB
May 21, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 7, 2026 RFCS
REFUSAL PROCESSED BY MPU
May 6, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 25, 2026 RFCR
NON-FINAL ACTION WRITTEN
Mar 24, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 27, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 27, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 22, 2026 REPR